- Fresenius SE anticipates organic revenue growth of 4% to 6% in 2025.
- Earnings before interest and taxes (EBIT) are expected to increase by 3% to 7% in 2025.
- Overall EBIT before special items was €646 million, surpassing the estimate of €639.6 million.
- Kabi EBIT before special items reached €340 million, exceeding the expected €331.9 million.
- Helios EBIT before special items came in at €339 million, slightly below the estimate of €339.3 million.
- Total sales were reported at €5.53 billion.
- Kabi sales amounted to €2.15 billion, ahead of the €2.12 billion estimate.
- Helios sales matched the estimate at €3.27 billion.
- The dividend per share for 2024 was set at €1, higher than the estimated €0.84.
- Fresenius Kabi’s organic revenue is expected to grow in the mid- to high-single-digit percentage range, with an EBIT margin between 16.0% and 16.5%.
- Fresenius Helios is projected to have organic revenue growth in the mid-single-digit percentage range, with an EBIT margin around 10%.
Fourth Quarter Results
2024 Year-End Results
2025 Outlook
“`
A look at Fresenius & KGaA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Fresenius KGaA, a global healthcare group, shows promising long-term potential based on its Smartkarma Smart Scores. With a solid value score of 4 and strong momentum score of 4, the company is positioned well for growth and performance. While its dividend score is lower at 1, indicating room for improvement in this area, Fresenius KGaA demonstrates resilience with a score of 3. The company’s focus on dialysis, hospital products, and medical care services, paired with its diverse range of pharmaceutical offerings, showcases a robust business model poised for continued success.
Looking ahead, Fresenius KGaA’s overall outlook, as reflected in its Smart Scores, suggests a favorable trajectory. With a growth score of 3 complementing its value and momentum strengths, the company is expected to sustain its position in the healthcare industry. As a global leader in providing essential healthcare products and services, Fresenius KGaA’s strategic positioning and product portfolio bode well for its long-term performance and value creation for investors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
